Internal Discoveries Generate Strong IP
ViaCyte maintains a broad intellectual property (IP) portfolio developed primarily through internal discovery.
ViaCyte has more than 450 issued patents worldwide (more than 80 in the U.S.) and more than 700 pending applications as of January 1, 2017.
ViaCyte’s patent portfolio covers many of the intermediary cell types generated when human pluripotent stem cells progress along the differentiation pathway to pancreatic progenitor cells, including mesendoderm and definitive endoderm. ViaCyte also has a proprietary protocol for generating more mature pancreatic endocrine cells in vitro. Methods for making the cells and implantable devices as well as their uses are also protected.